Company intelligence / Profile preview
GLWL Research, Inc.
Montreal, Quebec, Canadaglwlresearch.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
GLWL-01 was found to be safe and well tolerated in clinical trials. Pharmacological parameters confirmed the inhibition of GOAT following administration of GLWL-01. However, patients' eating behaviors, BMI, blood glucose, and total cholesterol were not modified in the Prader-Willi Syndrome trial.[7]
- Therapeutic areas
- EndocrinologyRare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Eli Lilly and Company (through Chorus division)TVM Capital Life Science
Beyond the preview
Go deeper on GLWL Research, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLWL Research, Inc..